Article

Daily Medication Pearl: Emflaza (Deflazacort)

Emflaza is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

Medication Pearl of the Day: Emflaza (Deflazacort)

Indication: Emflaza is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

Insights:

  • Dosing: The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally.
  • Dosage forms: Tablets: 6, 18 , 30 , and 36 mg-Oral Suspension: 22.75 mg/mL.
  • Adverse events: The most common adverse reactions (≥ 10% for Emflaza and greater than the placebo) are central obesity, cough, Cushingoid appearance, hirsutism, increased appetite, nasopharyngitis, pollakiuria, upper-respiratory-tract infection, and weight increase.
  • Mechanism of action: Deflazacort is a corticosteroid prodrug, whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown.

Source:

Prescribing Information | EMFLAZA® (deflazacort)

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Asthma COPD Breath Nebulizer And Mask Given By Doctor Or Nurse - Image credit: Angelov | stock.adobe.com
1 expert in this video
1 expert in this video
1 expert in this video
Psychiatric pharmacist and patient -- Image credit: NanSan | stock.adobe.com